Efficacy and pathogenetic justification for the use of vildagliptin in patients with type 2 diabetes mellitus

Efficacy and pathogenetic justification for the use of vildagliptin in patients with type 2 diabetes mellitus

Background. Dipeptidyl peptidase4 inhibitors, having incretin activity, influence the main pathogenetic mechanisms of type 2 diabetes mellitus (DM). Vildagliptin is an innovative dipeptidyl peptidase4 inhibitor with unique pharmacokinetic characteristics, the efficacy and safety of which have be...

Full description

Bibliographic Details
Main Author:	V.I. Pankiv
Format:	Article
Language:	English
Published:	Zaslavsky O.Yu. 2019-10-01
Series:	Mìžnarodnij Endokrinologìčnij Žurnal
Subjects:	type 2 diabetes mellitus vildagliptin glycated hemoglobin insulin resistance
Online Access:	http://iej.zaslavsky.com.ua/article/view/186055

Similar Items

First Russian DPP-4 inhibitor Gosogliptin comparing to Vildagliptin in type 2 diabetes mellitus patients
by: Karina Oganesovna Galstyan, et al.
Published: (2016-01-01)

Comparison of empagliflozin and vildagliptin for efficacy and safety in type 2 diabetes mellitus in the Pakistani population
by: Asima Khan, et al.
Published: (2022-08-01)

Type 2 diabetes mellitus: current international guidelines, personalized approach and real outpatient practice
by: V.I. Pankiv
Published: (2020-09-01)

Comparison of efficacy of add-on therapy of vildagliptin versus pioglitazone among Type 2 Diabetes Mellitus patients inadequately controlled on dual therapy of metformin plus sulfonylurea
by: Kirandeep Kaur
Published: (2014-02-01)

Cardiovascular outcomes of vildagliptin in patients with type 2 diabetes mellitus after acute coronary syndrome or acute ischemic stroke
by: Dong‐Yi Chen, et al.
Published: (2020-01-01)

Vildagliptin: optimal control in type 2 diabetes mellitus treatment
by: Alexander Sergeevich Ametov
Published: (2015-12-01)

Comparison of Vildagliptin-Metformin and Glimepiride-Metformin Treatments in Type 2 Diabetic Patients
by: Hyun Jeong Jeon, et al.
Published: (2011-10-01)

EDGE study in Russian Federation: efficacy and safety of vildagliptine in comparison with other oral antidiabetic agents in patients with type 2 diabetes mellitus
by: Gagik Radikovich Galstyan
Published: (2013-06-01)

Cost effectiveness of vildagliptin versus glimepiride as add-on treatment to metformin for the treatment of diabetes mellitus type 2 patients in Greece
by: Hara Kousoulakou, et al.
Published: (2017-09-01)

Long-Term Glycaemic Durability of Early Combination Therapy Strategy versus Metformin Monotherapy in Korean Patients with Newly Diagnosed Type 2 Diabetes Mellitus
by: Soon-Jib Yoo, et al.
Published: (2021-11-01)

Vildagliptin induced cutaneous leukocytoclastic vasculitis: A case report
by: Serhat Sayin, et al.
Published: (2018-03-01)

Vildagliptin Has a Neutral Association With Dementia Risk in Type 2 Diabetes Patients
by: Chin-Hsiao Tseng, et al.
Published: (2021-04-01)

A 4-Week, Two-Center, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of EOPatch in Well-Controlled Type 1 Diabetes Mellitus
by: Jiyun Park, et al.
Published: (2022-11-01)

The use of long-acting insulin degludec in adult patients with type 2 diabetes mellitus in real clinical practice in Russia
by: G. R. Galstyan
Published: (2023-02-01)

Pathogenetic substantiation and effectiveness of vildagliptin use inpatients with diabetes mellitus type 2
Published: (2009-09-01)

Vildagliptin: a new oral treatment for type 2 diabetes mellitus
by: Chantal Mathieu, et al.
Published: (2008-12-01)

Nanofibrous insulin/vildagliptin core-shell PLGA scaffold promotes diabetic wound healing
by: Chen-Hung Lee, et al.
Published: (2023-04-01)

Vildagliptin Treatment on the Portal Venous Pressure and Hepatosteatosis in Patients with Type 2 Diabetes Mellitus
by: Cumali KARATOPRAK, et al.
Published: (2018-01-01)

Pharmacogenetic aspects of vildagliptin treatment in patients with newly diagnosed type 2 diabetes mellitus
by: P. B. Shorokhova, et al.
Published: (2019-10-01)

Estimated Glycated albumin' levels early in pregnancy could detect women at risk to develop gestational diabetes mellitus
by: Amr Sharafeldeen *, et al.
Published: (2023-07-01)

The efficacy of therapy with DPP-4 inhibitors combined with insulin in patients with type 2 diabetes mellitus
by: Alexander Sergeevich Ametov, et al.
Published: (2011-12-01)

Frozen Shoulder in Type 2 Diabetes Mellitus
by: Atheer Ahmed Matloub, et al.
Published: (2010-06-01)

Predictive Clinical Parameters and Glycemic Efficacy of Vildagliptin Treatment in Korean Subjects with Type 2 Diabetes
by: Jin-Sun Chang, et al.
Published: (2013-02-01)

Serum Nesfatin-1 in patients with type 2 diabetes mellitus: A cross sectional study
by: Niyan Jassim Mohammad, et al.
Published: (2020-06-01)

Budget impact of vildagliptin
by: Orietta Zaniolo, et al.
Published: (2008-09-01)

The relationships between variables of glycated hemoglobin and diabetes distress in patients with type 1 and type 2 diabetes mellitus
by: V.I. Pankiv, et al.
Published: (2023-10-01)

The Role of Glycated Hemoglobin in the Diagnosis and Monitoring of Diabetes Mellitus
by: L.А. Lutsenko
Published: (2014-10-01)

The Role of Glycated Hemoglobin in the Diagnosis and Monitoring of Diabetes Mellitus
by: L.А. Lutsenko
Published: (2014-09-01)

GLYCOSYLATED HEMOGLOBIN AS A RISK ASSESSMENT OF THE CARDIOVASCULAR LESIONS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
by: О. Prystupiuk
Published: (2015-03-01)

Effects of Glycated Hemoglobin Level on Bone Metabolism Biomarkers in Patients with Type 2 Diabetes Mellitus
by: Zhao H, et al.
Published: (2020-05-01)

Seasonal Changes of HbA1c Levels in Type 2 Diabetes Mellitus Patients
by: Somaye Gholami, et al.
Published: (2019-03-01)

Results of a clinical trial of the efficacy and safety of vildagliptin and metformin fixed combination in real clinical practice in Russia (MASTER study)
by: N. A. Demidov, et al.
Published: (2021-02-01)

First trimester glycated hemoglobin in the prediction of gestational diabetes mellitus
by: Ahmad T.A Fattah, et al.
Published: (2020-01-01)

Microalbuminuria and glycated hemoglobin in children with type 1 diabetes mellitus
by: Magdy A. Omar, et al.
Published: (2015-03-01)

Possible applications of gliptins (dipeptidyl peptidase-4 inhibitors) in patients with type 2 diabetes mellitus on the various modes of insulin therapy
by: Gagik Radikovich Galstyan, et al.
Published: (2015-12-01)

Clinical implementetion of vildagliptin: data from recent studies comparing incretin-based medications
by: Elena Valer'evna Biryukova
Published: (2014-03-01)

Evaluation of sleep characteristics of children and adolescents with type 1 diabetes mellitus
by: Renata Aparecida e Silva, et al.
Published: (2021-10-01)

THE ROLE OF GLYCATED HEMOGLOBIN IN THE DIAGNOSIS AND IMPROVED PROGNOSIS OF DIABETES MELLITUS
by: E. V. Biryukova
Published: (2017-12-01)

Insulin pump therapy of type 1 diabetes mellitus in children and adolescents in the Moscow region
by: Elena Efimovna Petryaykina, et al.
Published: (2009-09-01)

Prevalence of hypoglycemic conditions in adolescents with type 1 diabetes mellitus in real clinical practice
by: I. M. Tsargasova, et al.
Published: (2023-01-01)